 |
|
|
| |
TMC435 with peginterferon and ribavirin in treatment-experienced HCV genotype 1 patients: the ASPIRE study, a randomised Phase IIb trial
|
| |
| |
Reported by Jules Levin
EASL 2012 April 18-22 Barcelona Spain
Stefan Zeuzem,1Thomas Berg,2Edward Gane,3Peter Ferenci,4Graham R. Foster,5MichaelW.Fried,6Christophe Hezode,7Gideon Hirschfield,8Ira Jacobson,9 Igor Nikitin,10PaulPockros,11Fred Poordad,12Oliver Lenz,13Monika Peeters,13VanithaSekar,14GoedeleDeSmedt,13Maria Beumont-Mauviel13
1JW Goethe University Hospital, Frankfurt, Germany; 2University Clinic Leipzig, Leipzig, Germany; 3Auckland Hospital Clinical Studies Unit, Auckland, New Zealand; 4Universitätsklinik für Innere Medizin III, Wien, Austria; 5Queen Marys University of London, London, UK; 6University of North Carolina at Chapel Hill, NC, USA; 7Hôpital Henri-Mondor, Université Paris-Est Créteil, France; 8Toronto Western Hospital Liver Centre, Toronto, Canada; 9Weill Cornell Medical College, New York, NY, USA; 10Russian State Medical University, Moscow, Russia; 11Scripps Clinic, La Jolla, CA, USA; 12Cedars-Sinai Medical Center, Los Angeles, CA, USA; 13 Janssen Infectious Diseases BVBA, Beerse, Belgium; 14 Janssen Research & Development LLC, Titusville, NJ, USA
|
| |
|
|
|
|
|
